Cogent BiosciencesCOGT
Market Cap: $1.15B
About: Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Employees: 164
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 6 (+2) [Q2]
38% more capital invested
Capital invested by funds: $747M [Q1] → $1.03B (+$283M) [Q2]
20.85% more ownership
Funds ownership: 106.92% [Q1] → 127.77% (+20.85%) [Q2]
17% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 47
4% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 26
1% more funds holding
Funds holding: 146 [Q1] → 147 (+1) [Q2]
37% less call options, than puts
Call options by funds: $850K | Put options by funds: $1.36M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Baird Joel Beatty 51% 1-year accuracy 18 / 35 met price target | 4%downside $10 | Neutral Maintained | 5 Sept 2024 |
HC Wainwright & Co. Robert Burns 40% 1-year accuracy 57 / 144 met price target | 62%upside $17 | Buy Maintained | 3 Sept 2024 |
JP Morgan Anupam Rama 51% 1-year accuracy 30 / 59 met price target | 81%upside $19 | Overweight Maintained | 7 Aug 2024 |
Needham Ami Fadia 55% 1-year accuracy 70 / 128 met price target | 72%upside $18 | Buy Reiterated | 7 Aug 2024 |
Needham Ami Fadia 55% 1-year accuracy 70 / 128 met price target | 72%upside $18 | Buy Reiterated | 27 Jun 2024 |